Bioresource - Genes & cognition
Research type
Research Study
Full title
BioResource - Genes & Cognition: Establishing a stratified population cohort of 40,000 people recallable for pre-clinical studies of neurodegeneration and dementia
IRAS ID
264644
Contact name
Patrick Chinnery
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust & the University of Cambridge
Clinicaltrials.gov Identifier
HVS/2018/2567 , Cambridge University Insurance reference
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Several new treatments for Alzheimer’s disease and neurodegenerative disorders have shown early promise, but have failed to deliver benefits when studied in patients in clinical trials. This is partly because the treatments were used too late, after irreversible brain damage had occurred. This proposal aims to ultimately establish the largest group of people in the world who have agreed to participate in medical research aimed at understanding early dementia and new treatment studies, so we can start to understand how the disease develops in its earlier stages and try new treatments before any irreversible damage occurs. \n\nThis will be achieved through the NIHR BioResource for Translational Research in Common and Rare Diseases, which will include over 200,000 healthy individuals with their genetic profile well-characterised. We will invite participants to complete on-line tests of memory and cognition to: (1) work out how likely it is that specific genetic variants cause dementia and neurodegeneration; and (2) establish a cohort of volunteers who can be recalled for future studies based on their detailed genetic and cognitive profile. This will provide a unique platform to advance our understanding of the early stages of dementia and the development of new treatments. By agreeing to be contacted about other research, members of this cohort may be invited to take part in other optional studies including natural history, biomarker and early interventional studies, accelerating the discovery of new treatments for Alzheimer’s disease and other neurodegenerative disorders.
REC name
North of Scotland Research Ethics Committee 1
REC reference
19/NS/0118
Date of REC Opinion
3 Jul 2019
REC opinion
Favourable Opinion